CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced the initiation and first patient enrollment in ReCePI, a randomized, double-blinded, controlled, parallel group, ...
Cerus Corporation (NASDAQ: CERS) announces that the FDA has approved its IDE to initiate a Phase 3 clinical trial, ReCePI, assessing INTERCEPT Red Blood Cells (RBCs) in patients undergoing complex ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) today announced it has received an investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) ...
General Motors is cutting output at one of its main electric-vehicle factories, the latest automaker to pull back on EVs as U.S. President Donald Trump's administration yanks federal support for green ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback